Company announcements

Announcement type

All

Price-sensitive

Stock code or name

leave blank for all companies

Headline

leave blank for all announcements

Sector

Market Cap ($m)

Announcement date

View top

announcements

Order By

Ascending

Descending

Reset Filters

Search Results

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Response to ASX Price Query	5 Feb 2014 9:52AM	$1.915	$0.012	fallen by 99.37%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Trading Halt	4 Feb 2014 2:56PM	$2.080	$0.012	fallen by 99.42%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Axiron Net Sales for the Quarter to 31 December 2013	31 Jan 2014 9:50AM	$2.320	$0.012	fallen by 99.48%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Axiron Launched in Brazil	28 Nov 2013 9:39AM	$2.510	$0.012	fallen by 99.52%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Lilly and Acrux file lawsuit against Actavis	13 Nov 2013 9:22AM	$2.590	$0.012	fallen by 99.54%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Axiron net sales, quarter to 30 September 2013	24 Oct 2013 9:36AM	$2.760	$0.012	fallen by 99.57%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Acrux Announces First European Approval for AXIRON	7 Oct 2013 9:43AM	$3.170	$0.012	fallen by 99.62%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Appendix 4E and Financial Report to 30 June 2013	27 Aug 2013 9:40AM	$3.260	$0.012	fallen by 99.63%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Axiron net sales, quarter to 30 June 2013	25 Jul 2013 8:28AM	$3.440	$0.012	fallen by 99.65%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Axiron launched in Canada	28 Jun 2013 12:07PM	$3.510	$0.012	fallen by 99.66%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Richter to commercialise estradiol spray in ex-US markets	27 Jun 2013 8:26AM	$3.540	$0.012	fallen by 99.66%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Axiron net sales, quarter to 31 March 2013	26 Apr 2013 8:28AM	$4.120	$0.012	fallen by 99.71%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Acrux provides half-year update	18 Feb 2013 9:30AM	$3.860	$0.012	fallen by 99.69%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Half Yearly Report and Accounts	18 Feb 2013 9:24AM	$3.860	$0.012	fallen by 99.69%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Allowance of underarm administration patent in United States	12 Feb 2013 10:15AM	$3.900	$0.012	fallen by 99.69%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	2012 AGM Presentation	22 Nov 2012 10:29AM	$2.830	$0.012	fallen by 99.58%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Dividend, June 2012 results and Axiron update	23 Aug 2012 4:26PM	$3.890	$0.012	fallen by 99.69%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Appendix 4E and Financial Report for 30 June 2012	23 Aug 2012 4:22PM	$3.890	$0.012	fallen by 99.69%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Recuvyra approved by FDA	26 Jun 2012 9:03AM	$4.200	$0.012	fallen by 99.71%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Patent application update	21 Jun 2012 3:33PM	$4.070	$0.012	fallen by 99.71%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Axiron Marketing Authorisation Granted in Australia	25 May 2012 9:41AM	$4.260	$0.012	fallen by 99.72%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Axiron market update	26 Apr 2012 9:00AM	$4.050	$0.012	fallen by 99.70%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Axiron marketing authorisation granted in Canada	12 Apr 2012 9:43AM	$3.890	$0.012	fallen by 99.69%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Acrux announces board changes	22 Feb 2012 9:09AM	$3.450	$0.012	fallen by 99.65%
Acrux Limited (ACR) ORDINARY FULLY PAID	Health Care	$6	Half Yearly Report and Accounts	22 Feb 2012 9:04AM	$3.560	$0.012	fallen by 99.66%

526 - 550 of 688 results

Page 22 of 28

+ Company announcements and prices are delayed by at least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.